News

Horizon Pharma said that the MONA (modified release prednisone for the treatment of nocturnal asthma) study is a two-stage, open-label, pilot trial assessing Lodotra’s treatment effect in patients

Following a detailed analysis of the efficacy and safety results from the RA programme, Roche and Biogen Idec have concluded that the overall benefit to risk profile of

With the initiation of the Phase I clinical studies for this compound, Evotec will receive a milestone payment of EUR2m. The compound, which was discovered and optimised within

Christian Behrenbruch, CEO of ImaginAb, said: “ImaginAb is pleased to have formalised this collaboration with the GSK CIC. Not only does GSK have an excellent biologics pipeline, but

InVasc Therapeutics said that one grant is to continue research and development of small molecule drugs for the prevention and treatment of hypertension and stroke based on derivatives

The results demonstrated anti-tumor immunity of oncolytic viruses and indicated strong efficacy of the viruses against solid tumor cancers. Untill now 200 patients have been treated with oncolytic

The findings, presented by Boehringer Ingelheim Pharmaceuticals at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in San Francisco, include data from a

Vect-Horus has revealed the publication of its first patent in the ‘Institut National de la Propriété Intellectuelle’ (INPI) on April 23, 2010 (publication number FR2937322). The patent aims

Phoenix’s initial product launches in North America are expected to include private label finished goods using its antibiotic APIs, such as bacitracin and polymyxin B sulfate, two of